Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Impact of hematuria on long term kidney outcomes in adults with immunoglobulin A nephropathy: a systematic literature review and meta-analysis.
Journal: Frontiers in nephrology
Published: June 03, 2026
Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy.
Journal: Kidney international reports
Published: October 15, 2025
Lower proteinuria is better for patients with IgA nephropathy: a systematic review.
Journal: Frontiers in nephrology
Published: October 10, 2025
ICD-10 codes for APOL1-mediated kidney disease.
Journal: Kidney international
Published: July 21, 2025
Clinical Characteristics and Disease Progression among Nondiabetic Patients with Apolipoprotein L1-Mediated Kidney Disease and Patients with Other CKD.
Journal: Kidney360
Published: June 18, 2025
Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults.
Journal: Glomerular diseases
Published: November 30, 2023
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply.
Journal: The New England journal of medicine
Published: June 28, 2023
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.
Journal: The New England journal of medicine
Published: March 15, 2023
Pharmacokinetic/pharmacodynamic and safety study of a single dose of evolocumab 140 mg in healthy Chinese subjects.
Journal: International journal of clinical pharmacology and therapeutics
Published: July 31, 2020
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study.
Journal: The Journal of bone and joint surgery. American volume
Published: May 03, 2020
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.
Journal: The Journal of bone and joint surgery. American volume
Published: January 25, 2020
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects.
Journal: Clinical pharmacology : advances and applications
Published: March 08, 2019
Last Updated: 09/26/2026